HB 1135 – Nitazene Derivatives (Similar SB 736)

This bill amends s. 893.03, F.S., adding nitazene derivatives to the list of Schedule I controlled substances, which has the potential to expand the number of offenders going to prison for drug offenses.

Per DOC, in FY 18-19, there were 1,689 new commitments to prison for the Schedule I drug offense category where nitazene derivatives will be included, and in FY 19-20, there were 931 new commitments. In FY 20-21, there were 779 new commitments, and there were 1,016 new commitments in FY 21-22. This drug offense category contains various kinds of drugs, so it is not possible to see how each drug contributes to the total number of new commitments. It is also not known how the addition of nitazene derivatives will impact the prison population. Furthermore, it is possible that the new commitments in the latter half of FY 21-22 have already been impacted by the Attorney General temporarily adding nitazene derivatives to Schedule I controlled substances in April of 2022.

CONFERENCE ADOPTED ESTIMATE: Positive Indeterminate

Requested by: Senate